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The recent discovery of activating mutations in the BRAF gene in many cutaneous melanomas led us to screen the genomic sequence
of BRAF exons 11 and 15 in a series of 48 intraocular (uveal) melanomas, together with control samples from three cutaneous
melanomas and the SK-Mel-28 cell line, which has a BRAF mutation. The same mutation was detected in two-thirds of our cutaneous
melanoma samples, but was not present in any uveal melanomas. This finding further underlines the distinction between uveal and
cutaneous melanomas, and suggests that BRAF inhibitors are unlikely to benefit patients with uveal melanoma.
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Uveal melanoma is the most frequent primary intraocular tumour
in Caucasian adults, having an annual incidence rate of 0.7 per
100000 people (Prescher et al, 1996). The eye is the most common
site for noncutaneous melanomas, accounting for approximately
80% of such lesions (Sisley et al, 2000) and accounting for 13% of
all deaths from melanoma because of its very high mortality rate
(Albert et al, 1992). Both uveal and cutaneous melanomas
originate from the melanocyte, but little is known about the
underlying molecular pathogenesis of uveal melanoma. This is in
contrast to cutaneous melanoma where there have been more
substantial advances in detecting mutations (Chin et al, 1998).
Both tumours differ significantly in their aetiology, with UV light
appearing to play little or no part in the causation of uveal
melanoma, unlike skin melanoma (Dolin et al, 1994). Uveal
melanomas spread haematogenously leading to liver metastasis,
whereas cutaneous melanoma spreads mainly via the lymphatics
(Seftor et al, 1999) with skin metastases a more common problem.
Unlike cutaneous melanoma, no genes or tumour-suppressor
pathways have so far been convincingly linked to uveal melanoma
(Edmunds et al, 2002).
It has recently been reported that a large proportion of
cutaneous melanoma tumours contain activating oncogenic
mutations in the BRAF gene (Davies et al, 2002). This is an
oncogene in the RAS–RAF–MEK–ERK–MAP kinase pathway
that mediates cellular response to growth signals. Genetic
alterations to key components of this pathway are known to
contribute to the development of many cancers (Pollock and
Meltzer, 2002). Activating RAS point mutations are known to be
found in more than 30% of human tumours, predominantly
pancreatic, colonic, and in up to 36% of cutaneous melanomas
(Demunter et al, 2001). BRAF is a gene that is regulated by RAS
binding, and was shown to have missense mutations in 66% of
primary melanoma tumours, 59% of melanoma cell lines, and 80%
of melanoma short-term cultures (Brose et al, 2002; Davies et al,
2002). Mutations have also been detected in up to 82% of
cutaneous melanocytic nevi (Pollock et al, 2003). Activation of this
pathway has been noted in uveal melanoma tumours although
mutations have not been detected in any of the RAS genes (H-, K,
and N-RAS) (Mooy et al, 1991; Soparker et al, 1993). This makes
BRAF an interesting candidate gene to screen in uveal melanoma
tumours because of BRAF mutation being a potential mechanism
for the activation of this pathway, and the fact that BRAF
mutations are not thought to be related to the effects of UV light
(Davies et al, 2002).
BRAF mutations were predominantly found in two small regions
of the kinase domain of the BRAF molecule. The majority of the
mutations were a single T-A base substitution at nucleotide 1796
in exon 15 of the BRAF gene, and in some of the adjacent codons.
A smaller number of mutations were also found in a region of exon
11, and other lower levels of mutations have been reported in these
codons in cancers including ovarian, sarcomas, lung (Brose et al,
2002), and colorectal tumours (Rajagopalan et al, 2002).
MATERIALS AND METHODS
We screened the genomic sequence of BRAF exons 11 and 15 in a
series of 48 uveal melanoma tumours, using primers taken from
Davies et al (2002). DNA was extracted from tumours removed
from enucleated eyes from Moorfields Eye Hospital as described
previously and used in a previous study (Edmunds et al, 2002). All
tumour samples were removed as part of patient treatment and
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ywith local ethical committee approval for use of the tissue in this
study, and the study protocol adhered to the tenets of the
Declaration of Helsinki. The median age of the patients was 61
years old, with a small bias towards male subjects (56%). These
tumours were predominantly choroidal (74% of tumours), with
smaller numbers of ciliary body (14%), and mixed choroidal–
ciliary body (12%) type. We also tested DNA from three cutaneous
melanoma metastases.
Polymerase chain reaction (PCR) products were amplified using
Bioline Taq (Bioline, London, UK) in the following conditions:
5min 961C initial denaturation, 961C3 0s ,5 5 1C 1min, 721C 30s for
30 cycles, followed by a final extension cycle for 5min at 721C
(Hybaid, Ashford, UK). Polymerase chain reaction products were
purified using a QIAquick PCR purification kit (QIAGEN, Crawley,
UK). Purified PCR products are then directly sequenced using Big-
Dye terminator chemistry and analysed on an AB Biosystems 377
automated sequencer (AB, Warrington, UK). As a positive control,
the cutaneous melanoma cell-line SK-MEL-28 DNA was used, that
was known to contain the exon 15 T1796A (V599E) mutation
(Davies et al, 2002). As a negative control, blood DNA from several
unaffected individuals was used.
Sequences were compared to the assumed wild-type sequence
from the nontumour DNA, and to the human BRAF sequence
(Genbank accession number: GI:179532). Sequences were aligned
with wild-type sequence traces and compared by eye. Particular
attention was given to the sequence around the two small regions
of the kinase domain of the BRAF molecule located in exons 11 and
15 that contain all of the published mutations.
RESULTS
The SK-MEL-28 cell-line exon 15 T1796A (V599E) mutation was
detected by sequencing, and the same mutation was also detected
in two-thirds of the skin melanoma tumours studied. This result
was expected as Davies et al (2002) had shown that 66% of the
malignant melanoma tumours screened had BRAF mutations, and
predominantly the T1796A mutation. In contrast to this finding,
we could not detect exon 11 or 15 BRAF mutations in any of the
uveal melanoma tumours screened. We were able to produce high-
quality sequencing to screen for mutations in 35 samples for exon
15 and 23 samples for exon 11 (Figure 1).
DISCUSSION
It is possible that, with direct sequencing, low levels of mutation
could have been missed, as it is not as sensitive a technique as
SSCP or DHPLC. Our tumour DNA samples were very pure
though, and there was unlikely to be any contamination from
normal tissues. Sequencing would not be able to detect mutant
alleles present at low frequency because of somatic mosaicism, but
the significance of very low levels of mutant tumour cells would be
questionable. It is also possible that there were mutations in other
areas of the BRAF gene, as we only screened exons 11 and 15, and
predominantly concentrated on the mutated hotspots. All pre-
viously reported mutations have been concentrated to these two
hotspot regions in the BRAF kinase domain, hence, mutations in
different regions of the molecule are unlikely to be able to activate
the oncogene in such a strong manner.
Here, we show another potentially important cancer-associated
gene that is not mutated in sporadic uveal melanoma. Many other
studies have found significant genetic (Naus et al, 2000; Soufir et al,
2000; Edmunds et al, 2002) and cytogenetic differences (Sisley et al,
2000) between the tumour types, despite both cells originating
from the same cell type. Uveal melanoma is less studied in
comparison to cutaneous melanoma, but to date no significant
levels of mutated tumour-suppressor genes have so far been
convincingly linked to it (Edmunds et al, 2002). Epigenetic
mechanisms of gene inactivation may play a more important role
in this tumour. If the RAS/RAF pathway is activated in uveal
melanoma, then it is unlikely to be because of activating mutations
in RAS or B-RAF, but other members of this pathway have yet to be
studied, including A-RAF, C-RAF (RAF1), and GAP1.
Our findings further highlight the fact that cutaneous and uveal
melanomas are very different tumours, and that the oncogenesis of
uveal melanoma uses very different mechanisms and genes to
cutaneous melanoma. This has implications for treatment, as
BRAF inhibitors are now undergoing clinical trials from which
uveal melanoma patients are unlikely to benefit. (Chow et al, 2001;
Coudert et al, 2001; Rudin et al, 2001; Cripps et al, 2002).
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